Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Sells $393,210.00 in Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 3,000 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total transaction of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This trade represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Axsome Therapeutics Stock Performance

NASDAQ:AXSM opened at $131.15 on Friday. Axsome Therapeutics, Inc. has a twelve month low of $64.11 and a twelve month high of $134.18. The company has a market cap of $6.36 billion, a P/E ratio of -20.08 and a beta of 1.05. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. The company’s 50-day moving average price is $97.84 and its 200-day moving average price is $93.27.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to analysts’ expectations of $98.71 million. During the same period in the previous year, the firm posted ($1.32) EPS. On average, sell-side analysts forecast that Axsome Therapeutics, Inc. will post -4.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on AXSM. Mizuho lifted their price target on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an “outperform” rating in a research report on Tuesday. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. HC Wainwright reissued a “buy” rating and set a $190.00 price target on shares of Axsome Therapeutics in a research report on Tuesday. Wells Fargo & Company boosted their target price on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $139.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, January 29th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $147.13.

Institutional Trading of Axsome Therapeutics

Several large investors have recently added to or reduced their stakes in AXSM. JPMorgan Chase & Co. boosted its position in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock valued at $19,062,000 after acquiring an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $2,599,000. PDT Partners LLC acquired a new stake in shares of Axsome Therapeutics during the 3rd quarter worth approximately $1,052,000. Pallas Capital Advisors LLC purchased a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $2,237,000. Finally, Captrust Financial Advisors acquired a new position in Axsome Therapeutics in the third quarter valued at approximately $514,000. 81.49% of the stock is currently owned by hedge funds and other institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.